A Phase 1 Study of Dabrafenib in Combination with Lapatinib in BRAF Mutant Thyroid Cancer (NCI #9354)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Dabrafenib (Primary) ; Lapatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Status changed from recruiting to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.